Dr. Wenjun Wei 魏文俊
Chief Physician
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical management of medullary and anaplastic thyroid cancer, surgical treatment of advanced or complex recurrent thyroid cancer, and endoscopic surgery for thyroid tumors.
Dr. Wei is Deputy Director of the Head and Neck Surgery Department at Fudan University Shanghai Cancer Center and a master’s supervisor. Trained under Professor Ji Qinghai, Dr. Wei completed visiting studies in otolaryngology–head and neck surgery at Stanford University Medical Center, focusing on da Vinci robotic surgery under Prof. Holsinger. Dr. Wei performs over 1,000 thyroid and head and neck malignancy surgeries annually.
Professional roles
- Member, Thyroid Committee, China Anti-Cancer Association
- Member, Thyroid Prevention and Treatment Committee, China Medical Promotion Association
- Secretary-General, Head and Neck Tumor Committee, Shanghai Anti-Cancer Association
- Secretary, Thyroid Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Wei Wenjun). Papers usually list the name as Wenjun Wei or Wei W.
Selected publications
66 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Br J Cancer, 2026 (senior author): Integrated multi-omics and single-cell analyses identify metabolic heterogeneity and therapeutic vulnerabilities in medullary thyroid cancer. PubMed 42098434
- Cell Rep Med, 2025 (senior author): A spatially resolved transcriptome landscape during thyroid cancer progression. PubMed 40157360
- J Clin Endocrinol Metab, 2024 (senior author): Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer. PubMed 38570918
- Cell Discov, 2022 (senior author): Integrated proteogenomic characterization of medullary thyroid carcinoma. PubMed 36344509
- J Clin Endocrinol Metab, 2021 (senior author): A 4 Gene-based Immune Signature Predicts Dedifferentiation and Immune Exhaustion in Thyroid Cancer. PubMed 33656532
- Transl Cancer Res, 2021 (senior author): Multiple lectin assays in detecting glycol-alteration status of serum NRG1 in papillary thyroid cancer. PubMed 35116628
- Front Oncol, 2021 (senior author): SNHG9, a Papillary Thyroid Cancer Cell Exosome-Enriched lncRNA, Inhibits Cell Autophagy and Promotes Cell Apoptosis of Normal Thyroid Epithelial Cell Nthy-ori-3 Through YBOX3/P21 Pathway. PubMed 34017682
- Front Oncol, 2021 (senior author): Identification of Key Functional Gene Signatures Indicative of Dedifferentiation in Papillary Thyroid Cancer. PubMed 33996555
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion